

SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF ISOXAZOLYL AZETIDIN-2-ONES AND THIAZOLIDIN-4-ONES

Ramu Kakkerla^{1*}, Srinivas Marri², Ramchander Merugu³
and Mavurapu Satyanarayana⁴

¹Department of Chemistry, Satavahana University, Karimnagar-505001, (Telangana) India

²Department of Chemistry, Siddhartha Degree and P.G. College, Narsampet-506132, (Telangana) India

³Department of Biochemistry, Mahatma Gandhi University, Nalgonda-508254, (Telangana) India

⁴Department of Pharmaceutical Chemistry, Telangana University, Nizamabad-503322, (Telangana) India

*E-mail: kakkerla2001@yahoo.co.in

ABSTRACT

A series of novel isoxazolyl azetidin-2-ones, **4a-h** and thiazolidin-4-ones, **5a-h** were synthesized from (*E*)-3-(methylimino)-*N*-(5-methylisoxazol-3-yl)butanamides, **3a-h**. The four-membered β -lactam ring was built by adding chloroacetyl chloride to butanamides, **3a-h** in the presence of triethylamine to give **4a-h**. Cyclocondensation of mercapto acetic acid with, **3a-h** in presence of anhydrous ZnCl₂ resulted in the formation of thiazolidin-4-ones, **5a-h**. The newly synthesized compounds, **4a-h** and **5a-h** were confirmed using IR, ¹HNMR, ¹³CNMR and mass spectral data and were evaluated for *in vitro* antibacterial activity. From the results, it is evident that the compounds **4d** and **5d** are showing exceptional antibacterial activity. Insilico ADME studies were performed and the results highlighted the designed compounds are safe to be considered as drug like molecules

Keywords: isoxazolyl thiazolidin-4-ones, isoxazolyl azetidin-2-ones, Schiff's bases, antibacterial activity.

© RASĀYAN. All rights reserved

INTRODUCTION


Medicinal chemists have paid much attention for the synthesis of heterocyclic compounds like isoxazoles, thiazolidinones and azetidin-2-ones, mainly due to their broad spectrum of biological activities. Amino isoxazole derivatives constitute an important class of heterocyclics that possesses anticancer¹, antibacterial², anticonvulsant³, analgesic⁴, and antifungal activity⁵. Thiazolidin-4-ones is a key pharmacophore in medicinal chemistry and is responsible for broad range of biological activities including antimicrobial^{6,7}, antioxidant⁸, anti-inflammatory⁹, analgesic¹⁰, antitumor¹¹, anticonvulsant¹² and antitubercular¹³, on the other hand, it is evident from the literature survey, that the 2-azetidinones are also associated with various pharmacological activities. 3-chloro monocyclic β -lactams derivatives having substitutions at 1 and 4 positions displayed antimicrobial¹⁴⁻¹⁶, anti-inflammatory¹⁷, antitubercular¹⁸ and antitumor¹⁹ activities. In view of the broad pharmacological activities of the isoxazoles, thiazolidin-4-ones and azetidin-2-ones, we envisioned the synthesis of hybrids of isoxazoles with thiazolidin-4-ones and azetidin-2-ones. Our quest in search of new biologically active molecules²⁰⁻²², herein we report the synthesis and anti bacterial activity of isoxazolyl azetidin-2-ones and thiazolidin-4-ones.

EXPERIMENTAL

Materials and Methods

Cintex melting point apparatus was used to record the melting points and are uncorrected. Merck precoated 60F 254 silica gel plates were used for TLC analysis and visualized under U.V. Light. IR Spectra (KBr Pellet) was recorded on a Perkin-Elmer BX series FT-IR Spectrometer. Proton and Carbon NMR spectra were recorded on a Bruker spectrometer (300 and 75 MHz, respectively) in the deuterated

chloroform solvent with TMS as an internal reference. ESI mass spectra were recorded on an Agilent LC-MSD mass spectrometer. Elemental analyses were performed on a Carlo Erba 106 and Perkin-Elmer model 240 analyzers. All the chemicals were procured from Sigma-Aldrich and are used as such without further purification.



Scheme-1: Synthesis of Isoxazolyl Azetidino-2-Ones and Thiazolidino-4-Ones

General Procedure

Synthesis of 2-(3-chloro-1,2-dimethyl-4-oxoazetidino-2-yl)-N-(5-methylisoxazol-3-yl)acetamides (4a-h)

To a well-stirred solution of compound (3, 0.01 mmol) and triethyl amine (0.02 mmol) in dry toluene (10 mL) was added drop wise chloroacetyl chloride (0.02 mmol) at room temperature. The reaction mixture was heated to reflux for 4 h and the separated solid was removed by filtration. The filtrate was concentrated under vacuum, and the residue was subjected to purification by column chromatography eluting with *n*-hexane and ethyl acetate (9:1).

Synthesis of 2-(2,3-dimethyl-4-oxothiazolidino-2-yl)-N-(5-methylisoxazol-3-yl)acetamide (5a-h)

A mixture of compound 3 (0.01 mmol) and mercaptoacetic acid (0.01 mmol) was dissolved in 1,4-dioxane (15 mL) and added 200 mg of anhydrous Zinc Chloride. The resulting solution was heated to reflux for 10-12 h and then cooled to room temperature. The reaction mixture was poured over crushed ice and the residue was extracted with ethyl acetate. The combined organic layer was washed with 10% aq. NaHCO₃ solution and dried over anhydrous Na₂SO₄. The solvent was distilled off under vacuum and the product was recrystallized from methanol.

Antibacterial Activity

The cultures were diluted with 0.9% saline and the final volume was made with concentration approximately 10⁵–10⁶ CFU/mL. The synthesized compounds were dissolved in DMSO. For agar disc diffusion method, Luria Bertani media was prepared, autoclaved and poured into sterilized Petri plates and then plates were spread separately with both two Gram positives and two Gram-negative bacterial strains. The synthesized compounds were added to the disc and plates were incubated at 37°C for 24 h. Inhibition Zones were measured (mm) and all experiments were repeated 3 times.

ADME Profiling

In our present study, the ADME properties of the synthesized compounds (4a-h and 5a-h) were determined by using Chemsketch ACD/I-Lab Version 8.0 software and results are summarized in Table-2.

RESULTS AND DISCUSSION

Synthesis of title compounds, 4a-h and 5a-h were accomplished as depicted in Scheme-1. Synthesis of isoxazolyl Schiff's bases 3a-h²³ was achieved by condensation of *N*-(5-methylisoxazol-3-yl)-3-

oxobutanamide²⁴ **1** with different primary amines, **2a-h**. These Schiff's base derivatives, **3a-h** underwent smooth cycloaddition reaction with chloroacetyl chloride in presence of triethyl amine to give **4a-h**. Isoxazolyl thiazolidin-4-ones were obtained by the cyclocondensation of **3a-h** with mercapto acetic acid in the presence of anhy. ZnCl₂ in 1,4-dioxane.

The synthesized compounds, **4a-h** and **5a-h** were confirmed by using IR, ¹HNMR, ¹³CNMR and Mass spectral data. Spectral data of all the synthesized compounds are in full agreement with proposed structures. The formation of compounds, **4a-h** was confirmed by newly observed ¹HNMR signal at δ 5.20 ppm and it is due to β -lactam -CHCl proton. ¹³CNMR of compound **4a** displayed -CHCl & -NCO carbon signals at δ 40.2 ppm and δ 168.3 ppm respectively. The observed signal at δ 3.82 ppm as a singlet in ¹HNMR of compound **5a** confirms the -SCH₂- of thiazolidine ring and ¹³CNMR of compound **5a** displayed peaks at δ 33.0 ppm and 170.0 ppm respectively due to the carbon of -SCH₂ and CO of the thiazolidine ring.

Spectroscopic Data for the Derivatives 4(a-h) and 5(a-h)

2-(3-Chloro-1,2-dimethyl-4-oxoazetididin-2-yl)-N-(5-methylisoxazol-3-yl)acetamide (4a)

Yield (79%) M.P. 160-162°C M.F. C₁₁H₁₄N₃O₃Cl Elemental Analysis: Calculated C, 48.63; H, 5.19; N, 15.47; Found C, 48.65; H, 5.18; Cl, N, 15.46. IR (KBr): 3225, 1712, 1672 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.61 (s, 3H, Aze-CH₃), 2.31 (s, 3H, isoxazole-CH₃), 3.02 (s, 3H, N-CH₃), 3.61 (s, 2H, CH₂), 5.21 (s, 1H, -CHCl), 6.21 (s, 1H, isoxazole-H), 9.31 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.1, 20.1, 32.0, 40.2, 58.2, 66.2, 95.0, 158.2, 168.3, 168.9, 170.2; ESI-MS: *m/z* 272 [M + H]⁺.

2-(3-Chloro-1-ethyl-2-methyl-4-oxoazetididin-2-yl)-N-(5-methylisoxazol-3-yl)acetamide (4b)

Yield (75%) M.P. 168-169°C; M.F. C₁₂H₁₆ClN₃O₃ Elemental Analysis: Calculated C, 50.44; H, 5.64; N, 14.71; Found C, 50.47; H, 5.62; N, 14.69. IR (KBr): 3251, 1708, 1662 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.20 (t, *J* = 7.2 Hz, 3H, N-CH₂-CH₃), 1.60 (s, 3H, Aze-CH₃), 2.28 (s, 3H, isoxazole-CH₃), 3.22 (q, *J* = 7.2 Hz, 2H, N-CH₂-CH₃), 3.50 (s, 2H, CH₂), 5.22 (s, 1H, -CHCl), 6.31 (s, 1H, isoxazole-H), 9.21 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.0, 12.2, 20.2, 40.9, 42.1, 58.9, 66.1, 95.1, 158.0, 169.0, 169.9, 171.2; ESI-MS: *m/z* 286 [M + H]⁺.

2-(3-Chloro-2-methyl-4-oxo-1-phenylazetididin-2-yl)-N-(5-methylisoxazol-3-yl)acetamide (4c)

Yield (76%) M.P. 178-179°C; M.F. C₁₆H₁₆ClN₃O₃ Elemental Analysis: Calculated C, 57.58; H, 4.83; N, 12.59; Found C, 57.57; H, 4.81; N, 12.58. IR (KBr): 3265, 1718, 1675 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.56 (s, 3H, Aze-CH₃), 2.31 (s, 3H, isoxazole-CH₃), 3.61 (s, 2H, CH₂), 5.30 (s, 1H, -CHCl), 6.29 (s, 1H, isoxazole-H), 7.18 (m, 2H, Ar-H), (m, 3H, Ar-H), 9.41 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.0, 20.9, 41.0, 59.0, 66.8, 95.0, 122.1, 122.3, 125.2, 130.0, 130.1, 142.3, 158.6, 168.8, 170.0, 171.1; ESI-MS: *m/z* 334 [M + H]⁺.

2-(3-Chloro-1-(4-chlorophenyl)-2-methyl-4-oxoazetididin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (4d)

Yield (80%) M.P. 184-186°C; M.F. C₁₆H₁₅Cl₂N₃O₃ Elemental Analysis: Calculated C, 52.19; H, 4.11; N, 11.41; Found C, 52.21; H, 4.10; N, 11.40. IR (KBr): 3230, 1720, 1681 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.58 (s, 3H, Aze-CH₃), 2.34 (s, 3H, isoxazole-CH₃), 3.58 (s, 2H, CH₂), 5.29 (s, 1H, -CHCl), 6.20 (s, 1H, isoxazole-H), 7.21 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.51 (d, *J* = 8.0 Hz, 2H, Ar-H), 9.15 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.2, 21.1, 39.2, 58.5, 66.3, 95.3, 124.3, 128.2, 129.0, 138.3, 159.2, 168.9, 170.0, 171.3; ESI-MS: *m/z* 368 [M + H]⁺.

Chloro-1-(4-methoxyphenyl)-2-methyl-4-oxoazetididin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (4e)

Yield (79%) M.P. 190-191°C; M.F. C₁₇H₁₈ClN₃O₄ Elemental Analysis: Calculated C, 56.13; H, 4.99; N, 11.55; Found C, 56.12; H, 4.98; N, 11.56. IR (KBr): 3281, 1721, 1679 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.59 (s, 3H, Aze-CH₃), 2.32 (s, 3H, isoxazole-CH₃), 3.52 (s, 2H, CH₂), 3.79 (s, 3H, OCH₃), 5.19 (s, 1H, -CHCl), 6.30 (s, 1H, isoxazole-H), 6.96 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.18 (d, *J* = 8.0 Hz, 2H, Ar-H),

9.58 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.0, 21.0, 40.4, 56.4, 58.2, 66.9, 96.0, 116.2, 124.7, 135.0, 154.1, 158.0, 168.2, 170.0, 171.0; ESI-MS: m/z 364 [M + H]⁺.

2-(1-Benzyl-3-chloro-2-methyl-4-oxoazetidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (4f)

Yield (75%) M.P. 199-201°C; M.F. C₁₇H₁₈ClN₃O₃ Elemental Analysis: Calculated C, 58.71; H, 5.22; N, 12.08; Found C, 58.70; H, 5.23; N, 12.10. IR (KBr): 3282, 1728, 1669 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.52 (s, 3H, Aze-CH₃), 2.30 (s, 3H, isoxazole-CH₃), 3.49 (s, 2H, CH₂), 4.51 (s, 2H, Ph-CH₂), 5.18 (s, 1H, -CHCl), 6.22 (s, 1H, isoxazole-H), 7.11- 7.30 (m, 5H, Ar-H), 9.81 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.1, 22.0, 40.1, 46.2, 58.7, 66.9, 95.1, 126.0, 127.0, 127.1, 127.9, 128.0, 134.0, 158.1, 169.0, 171.0, 171.2; ESI-MS: m/z 348 [M + H]⁺.

2-(1-(4-Chlorobenzyl)-3-chloro-2-methyl-4-oxoazetidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (4g)

Yield (78%) M.P. 207-209°C; M.F. C₁₇H₁₇Cl₂N₃O₃ Elemental Analysis: Calculated C, 53.42; H, 4.48; N, 10.99; Found C, 53.45; H, 4.50; N, 10.98. IR (KBr): 3243, 1722, 1659 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.55 (s, 3H, Aze-CH₃), 2.29 (s, 3H, isoxazole-CH₃), 3.52 (s, 2H, CH₂), 4.50 (s, 2H, Ph-CH₂), 5.09 (s, 1H, -CHCl), 6.28 (s, 1H, isoxazole-H), 7.20 (d, J = 8.0 Hz, 2H, Ar-H), 7.30 (d, J = 8.0 Hz, 2H, Ar-H), 9.38 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.2, 22.2, 41.0, 48.3, 57.9, 67.0, 95.2, 129.8, 131.0, 133.0, 135.1, 158.7, 169.0, 170.2, 171.2; ESI-MS: m/z 382 [M + H]⁺.

2-(1-(4-Methoxybenzyl)-3-chloro-2-methyl-4-oxoazetidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (4h)

Yield (76%) M.P. 215-216°C; M.F. C₁₈H₂₀ClN₃O₄ Elemental Analysis: Calculated C, 57.22; H, 5.34; N, 11.12; Found C, 57.24; H, 5.36; N, 11.13. IR (KBr): 3298, 1712, 1680 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.56 (s, 3H, Aze-CH₃), 2.29 (s, 3H, isoxazole-CH₃), 3.52 (s, 2H, CH₂), 3.80 (s, 3H, OCH₃), 4.50 (s, 2H, Ph-CH₂), 5.09 (s, 1H, -CHCl), 6.28 (s, 1H, isoxazole-H), 6.78 (d, J = 8.0 Hz, 2H, Ar-H), 7.09 (d, J = 8.0 Hz, 2H, Ar-H), 9.38 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.2, 23.0, 40.7, 48.7, 56.9, 57.9, 67.0, 95.2, 129.8, 131.0, 133.0, 135.1, 158.7, 169.0, 170.2, 171.2; ESI-MS: m/z 378 [M + H]⁺.

2-(2,3-Dimethyl-4-oxothiazolidin-2-yl)-N-(5-methylisoxazol-3-yl)acetamide (5a)

Yield (71%) M.P. 80-81°C; M.F. C₁₁H₁₅N₃O₃S Elemental Analysis: Calculated C, 49.06; H, 5.61; N, 15.60; Found C, 49.09; H, 5.62; N, 15.62. IR (KBr): 3312, 1701, 1678, 1220 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.62 (s, 3H, CH₃), 2.21 (s, 3H, isoxazole-CH₃), 2.94 (s, 3H, N-CH₃), 3.60 (s, 2H, CH₂), 3.82 (s, 2H, thiazolidine-CH₂), 6.21 (s, 1H, isoxazole-H), 9.08 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 11.9, 25.0, 33.0, 35.0, 48.1, 94.1, 63.3, 158.2, 168.0, 170.0, 170.2; ESI-MS: m/z 270[M + H]⁺.

2-(3-Ethyl-2-methyl-4-oxothiazolidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (5b)

Yield (75%) M.P. 91-93°C; M.F. C₁₂H₁₇N₃O₃S Elemental Analysis: Calculated C, 50.87; H, 6.05; N, 14.83; Found C, 50.89; H, 6.04; N, 14.81. IR (KBr): 3301, 1705, 1698, 1232 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.21 (t, J = 7.6 Hz, 3H, N-CH₂-CH₃), 1.69 (s, 3H, CH₃), 2.20 (s, 3H, isoxazole-CH₃), 3.22 (q, J = 7.6 Hz, 2H, N-CH₂-CH₃), 3.61 (s, 2H, CH₂), 3.80 (s, 2H, thiazolidine-CH₂), 6.09 (s, 1H, isoxazole-H), 9.41 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.0, 12.0, 26.0, 32.9, 41.0, 48.9, 63.0, 94.9, 157.8, 168.2, 169.8, 170.7; ESI-MS: m/z 284 [M + H]⁺.

2-(2-Methyl-4-oxo-3-phenylthiazolidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (5c)

Yield (72%) M.P. 108-110°C; M.F. C₁₆H₁₇N₃O₃S Elemental Analysis: Calculated C, 57.99; H, 5.17; N, 12.68; Found C, 57.98; H, 5.18; N, 12.68. IR (KBr): 3315, 1710, 1662, 1280 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.60 (s, 3H, CH₃), 2.31 (s, 3H, isoxazole-CH₃), 3.59 (s, 2H, CH₂), 3.84 (s, 2H, thiazolidine-CH₂), 6.02 (s, 1H, isoxazole-H), 7.30 (m, 5H, Ar-H), 9.05 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.2, 26.8, 33.0, 48.2, 63.8, 94.8, 123.2, 123.3, 126.7, 131.0, 131.1, 145.1, 158.3, 168.4, 170.2, 170.9; ESI-MS: m/z: 332 [M + H]⁺.

2-(3-(4-Chlorophenyl)-2-methyl-4-oxothiazolidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (5d)

Yield (70%) M.P. 99-100°C; M.F. C₁₆H₁₆ClN₃O₃S Elemental Analysis: Calculated C, 52.53; H, 4.41; N, 11.49; Found C, 52.56; H, 4.40; N, 11.47. IR (KBr): 3298, 1712, 1678, 1238 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.62 (s, 3H, CH₃), 2.33 (s, 3H, isoxazole-CH₃), 3.60 (s, 2H, CH₂), 3.90 (s, 2H, thiazolidine-CH₂), 6.12 (s, 1H, isoxazole-H), 7.18-7.32 (m, 4H, Ar-H), 8.91 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.1, 26.9, 33.0, 48.8, 63.0, 95.2, 128.1, 128.2, 124.0, 138.0, 158.9, 169.1, 170.0, 171.0; ESI-MS: m/z 366 [M + H]⁺.

2-(3-(4-Methoxyphenyl)-2-methyl-4-oxothiazolidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (5e)

Yield (71%) M.P. 114-115°C; M.F. C₁₇H₁₉N₃O₄S Elemental Analysis: Calculated C, 56.50; H, 5.30; N, 11.63; Found 56.52; H, 5.31; N, 11.61. IR (KBr): 3329, 1722, 1697, 1245 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.65 (s, 3H, CH₃), 2.33 (s, 3H, isoxazole-CH₃), 3.62 (s, 2H, CH₂), 3.80 (s, 3H, OCH₃), 3.90 (s, 2H, thiazolidine-CH₂), 6.05 (s, 1H, isoxazole-H), 6.78-6.92 (m, 4H, Ar-H), 9.25 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.0, 26.7, 33.0, 48.7, 64.0, 56.8, 94.6, 113.2, 121.2, 135.1, 157.3, 158.3, 169.2, 170.4, 171.2; ESI-MS: m/z 362 [M + H]⁺.

2-(3-Benzyl-2-methyl-4-oxothiazolidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (5f)

Yield (69%) M.P. 122-123°C; M.F. C₁₇H₁₉N₃O₃S Elemental Analysis: Calculated C, 59.11; H, 5.54; N, 12.17; Found C, 59.13; H, 5.55; N, 12.16. IR (KBr): 3309, 1718, 1661, 1218 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.66 (s, 3H, CH₃), 2.30 (s, 3H, isoxazole-CH₃), 3.61 (s, 2H, CH₂), 3.96 (s, 2H, thiazolidine-CH₂), 4.52 (s, 2H, Ph-CH₂), 6.19 (s, 1H, isoxazole-H), 7.18-7.32 (m, 5H, Ar-H), 9.51 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.3, 26.7, 33.0, 46.1, 48.2, 64.0, 94.6, 126.8, 127.0, 128.0, 128.8, 128.3, 140.3, 158.3, 169.8, 170.0, 171.1; ESI-MS: m/z 346 [M + H]⁺.

2-(3-(4-Chlorobenzyl)-2-methyl-4-oxothiazolidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (5g)

Yield (69%) M.P. 128-129°C; M.F. C₁₇H₁₈ClN₃O₃S Elemental Analysis: Calculated C, 53.75; H, 4.78; N, 11.06; Found 53.78; H, 4.79; N, 11.08. IR (KBr): 3311, 1703, 1679, 1227 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.68 (s, 3H, CH₃), 2.28 (s, 3H, isoxazole-CH₃), 3.60 (s, 2H, CH₂), 4.01 (s, 2H, thiazolidine-CH₂), 4.51 (s, 2H, Ph-CH₂), 6.25 (s, 1H, isoxazole-H), 6.72 (d, 2H, J = 8.0 Hz, Ar-H), 6.99 (d, 2H, J = 8.0 Hz, Ar-H), 9.14 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.2, 27.0, 33.0, 46.0, 48.0, 63.9, 95.0, 126.8, 128.0, 134.3, 135.3, 158.0, 169.0, 170.2, 171.0; ESI-MS: m/z 380 [M + H]⁺.

2-(3-(4-Methoxybenzyl)-2-methyl-4-oxothiazolidin-2-yl)-N-(5-methylisoxazol-3-yl) acetamide (5h)

Yield (78%) M.P. 115-116°C; M.F. C₁₈H₂₁N₃O₄S Elemental Analysis: Calculated C, 57.58; H, 5.64; N, 11.19; Found C, 57.57; H, 5.65; N, 11.21. IR (KBr): 3301, 1703, 1699, 1225 cm⁻¹; ¹HNMR (300 MHz, CDCl₃ δ ppm): 1.65 (s, 3H, CH₃), 2.30 (s, 3H, isoxazole-CH₃), 3.65 (s, 2H, CH₂), 3.79 (s, 3H, OCH₃) 3.99 (s, 2H, thiazolidine-CH₂), 4.54 (s, 2H, Ph-CH₂), 6.19 (s, 1H, isoxazole-H), 6.62 (d, 2H, J = 8.0 Hz, Ar-H), 7.02 (d, 2H, J = 8.0 Hz, Ar-H), 9.51 (s, 1H, NH); ¹³CNMR (75 MHz, CDCl₃ δ ppm): 12.2, 27.0, 33.0, 46.4, 48.0, 57.0, 63.9, 95.0, 116.2, 128.0, 130.2, 154.0, 158.0, 169.0, 170.2, 171.0; ESI-MS: m/z 376 [M + H]⁺.

Antibacterial Activity

The synthesized compounds, **4a-h** and **5a-h** were tested for antibacterial activity against Gram-positive organisms *Staphylococcus aureus* (MTCC 96), *Bacillus subtilis* (MTCC 121) and two Gram-negative organisms *Escherichia coli* (MTCC 43) and *Klebsiella pneumoniae* (MTCC 530). The compounds were tested in concentrations of 10 µg/mL and 20 µg/mL and the zones of inhibition were measured (mm) with *Gatifloxacin* as the standard drug. The results are presented in Table-1 and all the tested compounds (**4a-h** and **5a-h**) showed good to excellent antibacterial activity. The results indicate that the compounds **4a-h** are more potent than compounds **5a-h** in the series and this may be attributed to the presence of the β-lactam ring. *N*-alkyl substituted (*N*-methyl and *N*-ethyl) compounds **4a**, **4b**, **5a** and **5b** are less potent

when compared to all other compounds. Among the tested compounds, compounds **4d** and **5d** found to be the most effective against strains at higher concentration (20 $\mu\text{g/mL}$), with zone of inhibition (ZOI) values for **4d** are 24 ± 0.22 , 27 ± 0.37 , 21 ± 0.19 , 22 ± 0.17 respectively against MTCC 96, MTCC 121, MTCC 43 and MTCC 530 strains, followed by compound **5d** with ZOI values of 23 ± 0.31 , 24 ± 0.24 , 20 ± 0.29 , 20 ± 0.17 (Table-1). Rest of the compounds exhibited moderate to good antibacterial activity against different bacterial stains and are not selective. The enhanced activity of **4d** and **5d** may be attributed to the chloro substituent on the benzene ring.

Table-1: Antibacterial Activity of Synthesized Compounds 4a-h and 5a-h

Compound	Zone of Inhibition (mm \pm SD) ^a							
	Gram positive bacteria				Gram negative bacteria			
	<i>S. aureus</i> (MTCC 96)		<i>B. subtilis</i> (MTCC 121)		<i>E. coli</i> (MTCC 43)		<i>K. pneumonia</i> (MTCC 530)	
	10 $\mu\text{g/mL}$	20 $\mu\text{g/mL}$	10 $\mu\text{g/mL}$	20 $\mu\text{g/mL}$	10 $\mu\text{g/mL}$	20 $\mu\text{g/mL}$	10 $\mu\text{g/mL}$	20 $\mu\text{g/mL}$
4a	9 \pm 0.21	20 \pm 0.37	9 \pm 0.39	21 \pm 0.31	9 \pm 0.19	17 \pm 0.29	8 \pm 0.34	19 \pm 0.22
4b	10 \pm 0.32	22 \pm 0.26	10 \pm 0.28	23 \pm 0.28	10 \pm 0.21	20 \pm 0.31	10 \pm 0.26	20 \pm 0.36
4c	11 \pm 0.26	23 \pm 0.24	12 \pm 0.24	25 \pm 0.42	11 \pm 0.39	20 \pm 0.22	11 \pm 0.34	21 \pm 0.21
4d	13 \pm 0.34	24 \pm 0.22	12 \pm 0.26	27 \pm 0.37	12 \pm 0.28	21 \pm 0.19	12 \pm 0.21	22 \pm 0.17
4e	10 \pm 0.27	23 \pm 0.38	11 \pm 0.37	24 \pm 0.29	11 \pm 0.31	21 \pm 0.16	11 \pm 0.19	22 \pm 0.34
4f	12 \pm 0.19	23 \pm 0.21	12 \pm 0.41	25 \pm 0.25	11 \pm 0.24	21 \pm 0.27	12 \pm 0.26	22 \pm 0.21
4g	13 \pm 0.28	25 \pm 0.24	12 \pm 0.29	26 \pm 0.34	11 \pm 0.19	22 \pm 0.71	12 \pm 0.31	22 \pm 0.18
4h	11 \pm 0.31	22 \pm 0.23	11 \pm 0.27	25 \pm 0.19	10 \pm 0.27	21 \pm 0.35	11 \pm 0.42	20 \pm 0.25
5a	8 \pm 0.29	16 \pm 0.28	7 \pm 0.19	17 \pm 0.42	7 \pm 0.25	15 \pm 0.31	6 \pm 0.35	15 \pm 0.23
5b	8 \pm 0.26	18 \pm 0.39	9 \pm 0.31	20 \pm 0.17	8 \pm 0.17	18 \pm 0.29	9 \pm 0.31	18 \pm 0.21
5c	9 \pm 0.19	21 \pm 0.40	10 \pm 0.29	23 \pm 0.35	10 \pm 0.34	19 \pm 0.21	11 \pm 0.24	20 \pm 0.34
5d	11 \pm 0.35	23 \pm 0.31	11 \pm 0.27	24 \pm 0.24	10 \pm 0.23	20 \pm 0.29	12 \pm 0.29	20 \pm 0.17
5e	10 \pm 0.28	21 \pm 0.29	10 \pm 0.32	21 \pm 0.31	9 \pm 0.17	11 \pm 0.31	11 \pm 0.23	19 \pm 0.22
5f	8 \pm 0.25	16 \pm 0.17	8 \pm 0.36	17 \pm 0.19	8 \pm 0.23	15 \pm 0.37	7 \pm 0.34	15 \pm 0.39
5g	9 \pm 0.27	20 \pm 0.24	9 \pm 0.21	20 \pm 0.19	9 \pm 0.22	20 \pm 0.27	8 \pm 0.27	20 \pm 0.27
5h	8 \pm 0.22	17 \pm 0.21	8 \pm 0.40	18 \pm 0.31	8 \pm 0.18	16 \pm 0.19	8 \pm 0.33	16 \pm 0.42
Gatifloxacin	18	28	17	30	17	25	18	26

^aMean value of 3 trials

ADME Profiling

The results indicate that all the test compounds obey and are within the range of ADME parameters^{25,26}. The most potent compounds **4d** showed excellent absorption of 82.97% and **5d** showed 72.80% of absorption.

Table-2: Insilico prediction of ADME properties of synthesized compounds 4a-h and 5a-h

Compound	Lipinski Type Properties							
	% ABS ^a	MV ^b	MWt ^c	HBA ^d	HBD ^e	RotB ^f	TPSA ^g	mlogp ^h
4a	82.97	198.2	271.7	6	1	3	75.44	1.31
4b	82.97	214.4	285.73	6	1	4	75.44	1.58
4c	82.97	241.2	333.77	6	1	4	75.44	2.21
4d	82.97	252.1	368.21	6	1	4	75.44	2.72
4e	79.78	263.0	363.79	7	1	5	84.67	2.32
4f	82.97	257.4	347.8	6	1	5	75.44	2.18
4g	82.97	268.3	382.24	6	1	5	75.44	2.68
4h	79.78	279.2	377.82	7	1	6	84.67	2.29
5a	74.24	205.0	269.32	6	1	3	100.74	0.25
5b	74.24	225.5	283.35	6	1	4	100.74	0.54
5c	74.24	249.1	331.39	6	1	4	100.74	1.19
5d	74.24	261.1	365.83	6	1	4	100.74	1.71
5e	71.06	273.1	361.42	7	1	5	109.97	1.31

5f	74.24	263.3	345.42	6	1	5	100.74	1.17
5g	74.24	275.2	379.86	6	1	5	100.74	1.67
5h	71.06	287.3	375.44	7	1	6	109.97	1.28

^aPercentage of absorption (%ABS = 109- 0.349TPSA), ^bMolecular volume,

^cMolecular weight ≤ 500 , ^dHydrogen bond acceptor ≤ 10 , ^eHydrogen bond donar ≤ 5

^fRotatable bonds ≤ 10 , ^gTopological polar surface area $\leq 140^\circ\text{A}^2$,

^hPartition coefficient between *n*-Octanol and Water ≤ 5

CONCLUSION

In conclusion, we have prepared the isoxazolyl azetid-2-ones (**4a-h**) and isoxazolyl thiazolidin-4-ones (**5a-h**) and the compounds were evaluated for their antibacterial activity. Compounds **4d**, and **5d** have shown excellent antibacterial activity, and they can be exploited as potential bactericides after detailed study.

ACKNOWLEDGMENT

The authors are thankful to Department of Chemistry, University College of Science, Satavahana University, Karimnagar and also grateful to the CSIR-IICT, Hyderabad for providing ¹H NMR, ¹³C NMR and Mass spectral data.

REFERENCES

- W.S. Hamama, M.E. Ibrahim, and H.H. Zoorob, *J. Heterocyclic Chem.*, **54**, 341(2017), DOI: [10.1002/jhet.2589](https://doi.org/10.1002/jhet.2589)
- E. Nakayama, K. Watanabe, K. Miyauchi, K. Fujimoto, and J. Ide, *J. Antibiotic.*, **43**, 1122(1990), DOI: [10.7164/antibiotics.43.1122](https://doi.org/10.7164/antibiotics.43.1122).
- R.P. Clausen, E.K. Moltzen, J. Perregaard, S.M. Lenz, C. Sanchez, E. Falch, B. Frolund, T. Bolvig, A. Sarup, A. Larsson, P. Schousboe, and P. Krosgaard-Larsen, *Bioorg. Med. Chem.*, **13**, 895(2005), DOI: [10.1016/j.bmc.2004.10.029](https://doi.org/10.1016/j.bmc.2004.10.029).
- H. Kano, I. Adachi, R. Kido, and K. Hirose, *J. Med. Chem.*, **10**, 411(1967), DOI: [10.1021/jm00315a028](https://doi.org/10.1021/jm00315a028)
- P.B. Reddy, S.M. Reddy, E. Rajanarendar, and A.K. Muthy, *Indian Phytopathol.*, **37**, 389(1984).
- N.C. Desai, H.M. Satodiya, K.M. Rajpara, V.V. Joshi, and H.V. Vaghani, *Med. Chem. Res.*, **22**, 6063(2013), DOI: [10.1007/s00044-013-0600-x](https://doi.org/10.1007/s00044-013-0600-x).
- R.R. Mishra, K. S. Nimavat, and K. B. Vyas, *Rasayan J. Chem*, **5**, 214(2012).
- A.M. Isloor, D. Sunil, P. Shetty, S. Malladi, K.S.R. Pai, and N. Maliyakkl, *Med. Chem. Res.* **22**, 758(2012), DOI: [10.1007/s00044-012-0071-5](https://doi.org/10.1007/s00044-012-0071-5).
- S.H. Shelke, P.C. Mhaske, M. Nandave, S. Narkhade, N.M. Walhekar, and V.D. Bobade, *Bioorg. Med. Chem. Lett.*, **22**, 6373(2012), DOI: [10.1016/j.bmcl.2012.08.073](https://doi.org/10.1016/j.bmcl.2012.08.073).
- A. Deep, S. Jain, P.C. Sharma, P. Phogat, and M. Malhotra, *Med. Chem. Res.* **21**, 1652(2011), DOI: [10.1007/s00044-011-9679-0](https://doi.org/10.1007/s00044-011-9679-0).
- M. Sala, A. Chimento, and C. Saturnino, *Bioorg. Med. Chem. Lett.*, **23**, 4990(2013), DOI: [10.1016/j.bmcl.2013.06.051](https://doi.org/10.1016/j.bmcl.2013.06.051).
- M. Senthilraja, and V. Alagarsamy, *Rasayan J. Chem.*, **5**, 42(2012).
- K. Babaoglu, M.A. Page, V.C. Jones, M.R. McNeil, C. Dong, J.H. Naismith, and R.E. Lee, *Bioorg. Med. Chem. Lett.* **13**, 3227(2003), DOI: [10.1016/S0960-894X\(03\)00673-5](https://doi.org/10.1016/S0960-894X(03)00673-5).
- A.C. Ameya, and R.P. Nandini, *Molecules*, **12**, 2467(2007), DOI: [10.3390/12112467](https://doi.org/10.3390/12112467).
- S. K. Arifa Begum, K. Hemamalini, A. Rajani, D. Satyavati, N. D. V. R. Saradhi, P. K. Patra, K. Rupa, *Rasayan J. Chem.*, **6**, 207(2013).
- C. Patel, and C. P. Bhasin, *Rasayan J. Chem.*, **9**, 84(2016).
- J.B. Doherty, C.P. Dorn, P.L. Durette, P.E. Finke, M. MacCoss, S.G. Mills, S.K. Shah, S.P. Sahoo, S.A. Polo, and W.K. Hagmann, *WO 94*, **10**, 143(1994).
- K.A. Parikh, P.S. Oza, and A.R. Parikh, *Indian J. Chem*, **39B**, 716(2000).
- M. Noolvi, S. Agarwal, H. Patel, A. Badiger, M. Gaba, and A. Zambre, *Arabian J. Chem.* **7**, 219 (2014), DOI: [10.1016/j.arabjc.2011.02.011](https://doi.org/10.1016/j.arabjc.2011.02.011).

20. E. Rajanarendar, K. Ramu, A. Shiva Rami Reddy, and F.P. Shaik, *Ind. J. Chem.*, **44B**, 1284, (2006).
21. K. Ramu, M. Srinivas, M.P.S. Murali Krishna, M. Parusharamulu, and Y.N. Reddy, *Letters in Organic Chemistry*, **15**, 124(2018), DOI: [10.2174/1570178614666170623121207](https://doi.org/10.2174/1570178614666170623121207).
22. K. Ramu, M. Srinivas, M.P.S. Murali Krishna and M.V. Rajam, **57B**, June, (2018).
23. K. Ramu, V. Namratha, and M. Ramchander, *Int. J. Pharm. Bio. Sci.*, **7**, 192, (2016), DOI: [10.22376/ijpbs.2016.7.4.p192-196](https://doi.org/10.22376/ijpbs.2016.7.4.p192-196).
24. E. Rajanarendar, K. Ramu, and D. Karunakar, *Ind. J. Chem.*, **43B**, 2488, (2006).
25. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney, *Adv. Drug Deliv. Rev.* **23**, 3(1997), DOI: [10.1016/S0169-409X\(96\)00423-1](https://doi.org/10.1016/S0169-409X(96)00423-1).
26. D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kapple, *J. Med. Chem.*, **45**, 2615(2002), DOI: [10.1021/jm020017n](https://doi.org/10.1021/jm020017n).

[RJC-2040/2017]